Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.

Leukemia research - 1 Nov 2010

Du Juan, Yuan Zhengang, Zhang Chunyang, Fu Weijun, Jiang Hua, Chen Baoan, Hou Jian

Abstract excerpt

The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen. MM patients carrying t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Dexamethasone
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Survival Rate

Share to Thalidomide

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 20122728
DOI: 10.1016/j.leukres.2010.01.011

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20122728-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.PMID 20122728Read ↗

Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis.Semantic proximity Read ↗

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.Semantic proximity Read ↗

Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic polymorphisms and multiple myeloma risk: a meta-analysis.Semantic proximity Read ↗

Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma.Semantic proximity Read ↗

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple MyelomaSemantic proximity Read ↗

Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients.Semantic proximity Read ↗

[Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].Semantic proximity Read ↗

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Semantic proximity Read ↗

Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma.Semantic proximity Read ↗

Effects of TNFα, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases.Semantic proximity Read ↗

Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.